Pharmacoeconomics-open

Pharmacoeconomics-open

药物经济学-开放

  • Q2 JCR分区

期刊简介

《Pharmacoeconomics-open》是由Adis, Springer Healthcare出版社创办的英文国际期刊(ISSN: 2509-4262,E-ISSN: 2509-4254),该期刊长期致力于创新研究,主要研究方向为Multiple。作为SCIE收录期刊(JCR分区 Q2),本刊采用OA开放获取模式以发表等方向的原创性研究为核心(研究类文章占比84.21%%)。凭借严格的同行评审与高效编辑流程,期刊年载文量精选控制在76篇,确保学术质量与前沿性。成果覆盖Web of Science、Scopus等国际权威数据库,为学者提供推动高水平交流平台。

投稿咨询

投稿提示

Pharmacoeconomics-open审稿周期约为 8 Weeks 。该刊近年未被列入国际预警名单,年发文量约76篇,录用竞争适中,主题需确保紧密契合前沿。投稿策略提示:避开学术会议旺季投稿以缩短周期,语言建议专业润色提升可读性。

  • English 出版语言
  • 是否预警
  • SCIE 期刊收录
  • 76 发文量

JCR分区

按JIF指标学科分区 收录子集 分区 排名 百分位
学科:ECONOMICS ESCI Q2 207 / 597

65.4%

学科:HEALTH CARE SCIENCES & SERVICES ESCI Q3 91 / 174

48%

学科:HEALTH POLICY & SERVICES ESCI Q3 60 / 118

49.6%

学科:PHARMACOLOGY & PHARMACY ESCI Q3 222 / 354

37.4%

按JCI指标学科分区 收录子集 分区 排名 百分位
学科:ECONOMICS ESCI Q2 253 / 600

57.92%

学科:HEALTH CARE SCIENCES & SERVICES ESCI Q3 106 / 175

39.71%

学科:HEALTH POLICY & SERVICES ESCI Q3 80 / 119

33.19%

学科:PHARMACOLOGY & PHARMACY ESCI Q3 203 / 354

42.8%

CiteScore

CiteScore SJR SNIP CiteScore 排名
CiteScore:3.5 SJR:0.658 SNIP:0.698
学科类别 分区 排名 百分位
大类:Medicine 小类:Health Policy Q2 130 / 310

58%

大类:Medicine 小类:Pharmacology (medical) Q3 144 / 272

47%

大类:Medicine 小类:Pharmacology Q3 191 / 313

39%

期刊发文

  • Impact of Extrapolation Model Choices on the Structural Uncertainty in Economic Evaluations for Cancer Immunotherapy: A Case Study of Checkmate 067

    Author: Shao, Taihang; Zhao, Mingye; Liang, Leyi; Shi, Lizheng; Tang, Wenxi

    Journal: PHARMACOECONOMICS-OPEN. 2023; Vol. , Issue , pp. -. DOI: 10.1007/s41669-023-00391-5

  • Evaluation of Cost-Effectiveness of Adjuvant Osimertinib in Patients with Resected EGFR Mutation-Positive Non-small Cell Lung Cancer

    Author: Verhoek, Andre; Cheema, Parneet; Melosky, Barbara; Samson, Benoit; Shepherd, Frances A.; de Marinis, Filippo; John, Thomas; Wu, Yi-Long; Heeg, Bart; Van Dalfsen, Nadia; Bracke, Benjamin; Miranda, Miguel; Shaw, Simon; Moldaver, Daniel

    Journal: PHARMACOECONOMICS-OPEN. 2023; Vol. , Issue , pp. -. DOI: 10.1007/s41669-023-00396-0

  • Economic Evaluation of Nivolumab Versus Docetaxel for the Treatment of Advanced Squamous and Non-squamous Non-small Cell Lung Cancer After Prior Chemotherapy in China

    Author: Hu, Shanlian; Tang, Zhiliu; Harrison, James P.; Hertel, Nadine; Penrod, John R.; May, Jessica R.; Juarez-Garcia, Ariadna; Holdgate, Orban

    Journal: PHARMACOECONOMICS-OPEN. 2023; Vol. , Issue , pp. -. DOI: 10.1007/s41669-022-00383-x